Login to Your Account

Clinic Roundup

Monday, January 30, 2012
• Seattle Genetics Inc., of San Francisco, and Millennium, of Cambridge, Mass., a unit of Takeda Pharmaceuticals Co. Ltd., reported interim results from 32 patients treated to date in a Phase I trial of Adcetris (brentuximab vedotin) in combination with or sequentially with chemotherapy in newly diagnosed systemic anaplastic large-cell lymphoma (sALCL) and other CD30-postive mature T-cell lymphoma patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription